How to Help Your Patients Save Money on Releuko: A Provider's Guide to Savings Programs

Releuko (filgrastim-ayow) carries a wholesale acquisition cost of approximately $2,280 per injection at full list price. While most oncology patients receive it under the medical or pharmacy benefit, out-of-pocket costs can still be significant — particularly for patients with high-deductible plans, Medicare, or inadequate specialty tier coverage. As a provider, your team plays a critical role in navigating these financial barriers. This guide covers every savings lever available for Releuko in 2026.

Understanding the Cost Landscape

Before choosing a savings strategy, understand the payment environment your patient is in:

Medicare Part B (clinic/buy-and-bill): Releuko is covered at 80% of the Medicare-approved amount after the Part B deductible. Patient is responsible for 20% coinsurance (~$35–$80 per injection depending on strength and ASP). Medigap/supplemental plans may cover the 20%.

Medicare Part D (specialty pharmacy): Coverage and tier placement vary by plan. Post-IRA reforms cap out-of-pocket drug costs at $2,000/year for Medicare Part D beneficiaries starting in 2025, which significantly benefits high-cost biologic users.

Commercial insurance (medical benefit): Typically billed under the medical benefit for clinic administration. Copays are negotiated, but cost-sharing can range from $0–$200+ per cycle depending on the plan.

Commercial insurance (pharmacy benefit): When dispensed through a specialty pharmacy for home use, Releuko is covered under the pharmacy benefit. Specialty tier copays can range from $100–$500+ per month without assistance.

Uninsured: Cash price ~$489–$625 per injection with discount programs. Patient assistance programs are the primary option.

Strategy 1: Optimize Formulary Selection

For patients on commercial plans that prefer Zarxio as the formulary G-CSF biosimilar, using the preferred product often results in lower patient out-of-pocket costs with no meaningful clinical difference. Before prescribing Releuko specifically, check whether:

The patient's plan has a preferred G-CSF biosimilar and what their cost-sharing difference is

Whether the indication being treated has any clinically relevant differences between available biosimilars (e.g., Releuko is not preferred for stem cell mobilization — use Zarxio, Nivestym, or Neupogen)

When Releuko is clinically preferred or required, document the rationale clearly for PA purposes

Strategy 2: Submit PAs Proactively and Appeal Denials

Prior authorization delays are a leading cause of financial and clinical disruption for Releuko patients. To minimize impact:

Submit the PA 7–10 business days before the first anticipated dose

Include NCCN guideline citations supporting G-CSF use for the specific regimen

If denied for Releuko specifically (step therapy required), appeal with documentation that the preferred alternative is clinically contraindicated or unavailable, or simply prescribe the preferred product to avoid the PA battle when Releuko isn't specifically required

For urgent denials, request an expedited review — insurers are legally required to respond to expedited reviews within 72 hours for urgent medical conditions

Strategy 3: Leverage Amneal's Patient Assistance Program

Amneal Pharmaceuticals offers patient assistance for Releuko through its patient support infrastructure. Your clinical staff should know the current eligibility criteria and application process:

Copay assistance: For commercially insured patients facing high specialty tier copays. Note: Copay cards cannot be used for Medicare or Medicaid patients (federal anti-kickback considerations).

Free medication program: For uninsured or underinsured patients meeting income-based eligibility criteria. Usually requires income verification and prescriber attestation.

Assign this responsibility to your patient financial navigator, social worker, or prior authorization specialist. Do not wait for the patient to ask — screen for eligibility at initial treatment planning.

Strategy 4: Third-Party Foundation Support

When manufacturer assistance is unavailable (e.g., for Medicare patients), independent charitable foundations can fill the gap:

Patient Advocate Foundation Co-Pay Relief (PAF CPR) — Cancer-specific copay relief for commercial and Medicare patients

HealthWell Foundation — Grants for specialty drug copays including oncology biologics; income-based

PAN Foundation (Patient Access Network) — Co-pay assistance for underinsured patients with serious illness

NeedyMeds and RxAssist — Searchable databases of all available manufacturer and foundation assistance programs

Strategy 5: Hospital Financial Assistance and Charity Care

For patients receiving Releuko as a clinic-administered injection in a hospital-based oncology center, hospital financial assistance programs are an often-underutilized resource. Nonprofit hospitals are required by law (under Section 501(r) of the Internal Revenue Code) to offer financial assistance to eligible patients. This can extend to medications administered during inpatient and outpatient visits, including Releuko. Ensure your hospital's financial counselors are screening oncology patients at intake for financial assistance eligibility.

How medfinder Can Help Your Patients

For patients managing self-administered Releuko who need help finding it in stock or at a lower price, medfinder helps by calling local pharmacies to identify availability. This reduces the burden on your care team and helps patients avoid treatment gaps due to supply issues. For the patient-facing version of this savings guide, see How to Save Money on Releuko in 2026.